mRNA-3927 for Propionic Acidemia
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
- Age
- 1 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- ModernaTX, Inc. · Industry
This trial is looking for people with propionic acidemia who have already participated in a previous study. Participants will receive mRNA-3927, and the study will assess its long-term safety.
You may be able to join if
- I have participated in Study mRNA-3927-P101.
- I have completed the End of Treatment visit in Study mRNA-3927-P101.
You may not be able to join if
- I am not expected to benefit from continued mRNA-3927 treatment, according to the doctor.
- I have a medical condition that may put me at increased risk in this study.
- I have had a liver or kidney transplant.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Loading trial locations…